Abrdn logo

Abrdn

Europe, Edinburgh, City of, United Kingdom, Edinburgh

Description

Abrdn enables its clients to plan, save, and invest for their futures.

Investor Profile

Abrdn has made 20 investments, with 7 in the past 12 months and 15% as lead.

Stage Focus

  • Series A (20%)
  • Series B (20%)
  • Series C (15%)
  • Private Equity (15%)
  • Series Unknown (10%)
  • Post Ipo Equity (5%)
  • Post Ipo Debt (5%)
  • Debt Financing (5%)
  • Post Ipo Secondary (5%)

Country Focus

  • United States (45%)
  • United Kingdom (25%)
  • Canada (10%)
  • India (5%)
  • Argentina (5%)
  • Finland (5%)
  • Malaysia (5%)

Industry Focus

  • Biotechnology
  • Health Care
  • Life Science
  • Medical
  • Financial Services
  • Software
  • Pharmaceutical
  • Therapeutics
  • Oncology
  • Biopharma
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Abrdn frequently co-invest with?

Omega Funds
Europe, Geneve, Switzerland, Geneva
Co-Investments: 2
Chase Capital Partners
North America, New York, United States, New York
Co-Investments: 2
T. Rowe Price
North America, Maryland, United States, Baltimore
Co-Investments: 2
TCG Crossover
North America, California, United States, Palo Alto
Co-Investments: 2
RiverVest
North America, Missouri, United States, St Louis
Co-Investments: 2
Digitalis Ventures
North America, New York, United States, New York
Co-Investments: 2
Marshall Wace
Europe, England, United Kingdom, London
Co-Investments: 2
F-Prime Capital
North America, Massachusetts, United States, Cambridge
Co-Investments: 2
Logos Capital
North America, California, United States, San Francisco
Co-Investments: 2
Janus Henderson Investors
Europe, England, United Kingdom, London
Co-Investments: 2

What are some of recent deals done by Abrdn?

Arbor Biotechnologies

Cambridge, Massachusetts, United States

Arbor Biotechnologies is a biotechnology company specializing in next-generation gene editing therapeutics to treat genetic diseases.

BiopharmaBiotechnologyLife Science
Series CMar 18, 2025
Amount Raised: $73,900,000
Atalanta Therapeutics

Boston, Massachusetts, United States

Atalanta Therapeutics is a biotechnology company pioneering new treatment options for neurodegenerative diseases.

BiotechnologyHealth CareLife Science
Series BJan 28, 2025
Amount Raised: $97,000,000
Aviceda Therapeutics

Cambridge, Massachusetts, United States

Aviceda Therapeutics is a late-stage pre-clinical biotech company developing drugs for treating glyco-immune diseases.

BiotechnologyHealth CareLife SciencePharmaceuticalTherapeutics
Series CJan 7, 2025
Amount Raised: $207,500,000
Alpha9 Theranostics

Vancouver, British Columbia, Canada

Alpha9 Theranostics is a biopharma company that focuses on radiotherapeutics for the treatment of solid and hematologic malignancies.

BiotechnologyMedicalProduct Research
Series COct 23, 2024
Amount Raised: $175,000,000
Radiant Biotherapeutics

Toronto, Ontario, Canada

Radiant is a biotechnology company developing the next generation of multi-specificity.

BiotechnologyTherapeutics
Series ASep 11, 2024
Amount Raised: $35,000,000
Third Arc Bio

Boston, Massachusetts, United States

Third Arc Bio is a biotech company developing multifunctional antibodies for inflammatory and immunology diseases.

BiotechnologyHealth CareLife ScienceMedicalOncology
Series AJul 23, 2024
Amount Raised: $165,000,000
Qlaris Bio

Wellesley, Massachusetts, United States

Qlaris Bio focuses on developing first-in-class therapies for serious and debilitating ophthalmic diseases.

BiotechnologyHealth CareMedical
Series BApr 30, 2024
Amount Raised: $24,000,000
Sammaan Capital

Mumbai, Maharashtra, India

Sammaan Capital offers home loans in the affordable housing segment.

CreditFinancial ServicesLendingReal Estate
Post Ipo DebtMar 27, 2024
Amount Raised: $347,887,202
Engrail Therapeutics

San Diego, California, United States

Engrail Therapeutics is a developer of medicines to transform the lives of patients with life-limiting diseases of the nervous system.

Health CareLife ScienceMedicalPharmaceutical
Series BMar 19, 2024
Amount Raised: $157,000,000
Etelä-Savon Energia

Mikkeli, Eastern Finland, Finland

Etelä-Savon Energia produces light,heat and energy savings.

Energy
Private EquityNov 6, 2023